Last reviewed · How we verify
Consolidation Cycle A6 — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Consolidation Cycle A6 (Consolidation Cycle A6) — Nationwide Children's Hospital. Consolidation Cycle A6 is a chemotherapy regimen used in pediatric acute lymphoblastic leukemia (ALL) treatment to eliminate residual leukemic cells after initial induction therapy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Consolidation Cycle A6 TARGET | Consolidation Cycle A6 | Nationwide Children's Hospital | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Consolidation Cycle A6 CI watch — RSS
- Consolidation Cycle A6 CI watch — Atom
- Consolidation Cycle A6 CI watch — JSON
- Consolidation Cycle A6 alone — RSS
Cite this brief
Drug Landscape (2026). Consolidation Cycle A6 — Competitive Intelligence Brief. https://druglandscape.com/ci/consolidation-cycle-a6. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing